Latest 10-Q quarterly reports

Equator Beverage Company announced a significant increase in revenue and net income for the second quarter of 2026, driven by operational efficiencies and a substantial tax benefit.

BlueOne Technologies, Inc. filed its Q2 2026 10-Q, revealing a significant decrease in revenue and continued operating losses, raising substantial doubt about its ability to continue as a going concern.

Uwharrie Capital Corp announced a significant increase in net income for the second quarter of 2026, driven by robust deposit growth and a notable gain from a Visa stock exchange.

Chain Bridge Bancorp, Inc. (CBNA) announced a significant increase in net income and assets for the second quarter of 2026, driven by strong net interest income and noninterest income growth.

AsiaFIN Holdings Corp. announced a substantial 50.5% increase in revenue for the second quarter of 2026, returning to profitability after a period of net loss.

Vor Biopharma Inc. filed its Q2 2026 Form 10-Q, detailing ongoing clinical trials for telitacicept and significant net losses, while highlighting cash runway into early 2029.

Microbot Medical Inc. announced its Q2 2026 financial results, showing initial revenues from its LIBERTY Endovascular Robotic System following its full market release.

United-Guardian, Inc. announced a 10% increase in net sales for Q2 2026 and a 12% increase for the first half, driven by pharmaceutical and cosmetic ingredient sales, alongside improved net income.

Future Vision II Acquisition Corp. reports on its financial status for the quarter ended June 30, 2026, highlighting ongoing efforts to secure a business combination before its extended deadline, with a significant risk of liquidation if unsuccessful.

TON Strategy Company's Q2 2026 results show a significant surge in revenue from GRAM staking, alongside a substantial unrealized gain on digital assets, though operating expenses and legal matters persist.

Mereo BioPharma Group plc filed its Q2 2026 10-Q, detailing continued net losses, reduced R&D spending, and a significant new licensing agreement for alvelestat.

Energy Focus, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting significant revenue increases but also continued net losses and a substantial accumulated deficit.

Adagio Medical Holdings, Inc. reported continued net losses and significant cash burn in its Q2 2026 10-Q filing, raising substantial doubt about its ability to continue as a going concern, despite advancing its vCLAS Ventricular Ablation System through clinical trials and regulatory submissions.

Imunon, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development and significant financial challenges, including substantial doubt about its ability to continue as a going concern.

Barnwell Industries, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a reduced net loss and progress in divesting non-core assets.

Theriva Biologics, Inc. reported continued operating losses and substantial accumulated deficit in its Q2 2026 10-Q filing, raising significant doubts about its ability to continue as a going concern, despite positive clinical trial updates.

Magellan Copper & Gold Corp. filed its Q2 2026 Form 10-Q, detailing continued operating losses, a significant accumulated deficit, and substantial doubt regarding its ability to continue as a going concern.

Protara Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its TARA-002 and IV Choline Chloride programs, alongside financial performance and corporate updates.

LB Pharmaceuticals Inc. reported a substantial increase in research and development expenses and a widening net loss for the second quarter of 2026, driven by ongoing clinical trials for its lead product candidate, LB-102.

Coya Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development efforts, increased operating expenses, and a continued net loss, while highlighting the need for future capital.

Prelude Therapeutics Incorporated announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its oncology pipeline and a significant capital raise.

Smithfield Foods announced its Q2 2026 results, showcasing increased net income and operating profit, driven by strategic initiatives and improved segment performance.

Theravance Biopharma announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right, following a strategic review.

DPC Holdings PLC announced its second quarter 2026 financial results, highlighting revenue growth driven by the aerospace and IGT sectors, but also reporting a significant increase in net loss primarily due to a substantial rise in management incentive plan expenses.

Big Sky Industrial Inc. (BSIN) filed its Q2 2026 Form 10-Q, reporting a net loss of $2.3 million, with revenues impacted by declining oil and gas production but bolstered by higher oil prices.

Zura Bio Limited reported a net loss of $26.3 million for Q2 2026, with increased R&D expenses, while maintaining a substantial cash balance of $205.1 million.

Sagimet Biosciences Inc. reported a substantial increase in cash and cash equivalents following a $175 million underwritten offering, while also detailing progress in its clinical-stage drug development programs for acne and MASH.

C4 Therapeutics has entered into a significant research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop degrader-antibody conjugates (DACs).

908 Devices Inc. announced its Q2 2026 results, showcasing a 23% year-over-year revenue increase to $16.1 million, driven by product sales, alongside improved gross margins, while continuing to manage net losses.

Intensity Therapeutics reports continued net losses and operational challenges, raising substantial doubt about its ability to continue as a going concern, despite advancements in its clinical trial programs.